A special committee of 23andMe’s board rejected CEO Anne Wojcicki’s latest offer to take the company private.
Sofinnova Partners raises €1.2B across investment strategies, plans to fund 50-60 new startups in life sciences under chairman Antoine Papiernik's leadership.
Pliant Therapeutics discontinues Phase 2b trial of bexotegrast for idiopathic pulmonary fibrosis due to safety concerns, but ...
GSK, Amgen and AstraZeneca released positive data supporting their rival drugs in a condition called chronic rhinosinusitis ...
Protagonist Therapeutics reported a clean Phase 3 win on Monday for rusfertide — its rare blood disorder therapy — putting it ...
Lexicon's non-opioid drug pilavapadin fails Phase 2b pain trial at 20mg dose, but shows promise at 10mg. Company plans Phase ...
M223, a preclinical drug for inflammatory diseases, with potential milestone payments of $777.5M plus royalties.
Biohaven’s potassium channel drug has failed a late-stage study in bipolar mania, according to a statement in the company’s ...
For years, artificial intelligence has been a topic of discussion in pharmaceutical manufacturing, but adoption has been slow ...
Frazier Life Sciences and a cadre of well-known biotech investors are coming together for a new startup in the antibody-drug ...
After Phase 3 depression setback, Neumora pauses two trials to make changes, scraps another
Neumora pauses two Phase 3 trials of navacaprant for depression after earlier trial failure, CEO Paul Berns makes changes to ...
The higher prices of two COPD inhalers from GSK that are targeted in the second round of government drug price negotiations ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback